←
Sia Daneshmand, M.D.1,347 posts
Sia Daneshmand, M.D. avatar✓

Sia Daneshmand, M.D. ✓

@siadaneshmand

Professor of Urology and Oncology (Clinical Scholar) Director of Urologic Oncology Director of Clinical Research Urologic Oncology Fellowship Director USC

◷ Joined June 2009▧ 124 Photos and videos
Sia Daneshmand, M.D. avatar
Sia Daneshmand, M.D.@siadaneshmand·Oct 23

It’s with mixed emotions and deep gratitude that I will be leaving USC after 17 years to begin a new exciting chapter @UclaUrology as Director of the Institute of Urologic Oncology and Division Chief of Urologic Oncology. Forever thankful for the trainees, colleagues and patients who have shaped my journey. Grateful to @uroegg and @UCLAHealth leadership for their confidence and vision, and excited to build on their remarkable legacy of excellence.

Post attachment
Alex Zhu avatar
⟳ Sia Daneshmand, M.D. retweeted
Alex Zhu@alexzhuDO·Oct 28

Really interesting trial in progress (PRESERVE trial) @UroAlsyouf @siadaneshmand @GU_BigWhacks Randomizing patients 1:1 to facial sparing vs. standard inguinal orchiectomy. Endpoint = PRO’s Personally have seen a difference in my own experience. Excited to see final results

Post attachment
Sia Daneshmand, M.D. avatar
Sia Daneshmand, M.D.@siadaneshmand·Oct 17

🌺 As President of @AUAWest, and @DanLinMD as Program chair, we are excited to welcome colleagues to #SurgeWest2026 in Maui, Oct 25–30! 🌴 Outstanding science, innovation, education & fellowship await at the Best Week in Urology! Up to 33.50 AMA PRA Category 1 Credits™ Join us in person or virtually! 🔗 surgewest.org/ #WSAUA26 @DanLinMD @MarkTysonMD @garywchien @PReyblat @BrianDutyMD_MBA @EugeUrology @KKseattle @UroCancerMD

Post attachment
Sumanta K. Pal, MD, FASCO avatar
⟳ Sia Daneshmand, M.D. retweeted
Sumanta K. Pal, MD, FASCO@montypal·Oct 7

⭐️SAVE THE DATE: MARCH 5, 2027⭐️ We will be convening the 2027 So Cal GU Research Forum on this date at the Waterfront Hilton in #HuntingtonBeach, CA. If you are a clinician with interest in GU cancers in the #Socal area, you will not want to miss this. Our format is different: our agenda focuses exclusively on #clinicaltrials in the area, and we leave lots of time on the agenda for collaboration. Looking forward to seeing you there!

Post attachment
Shilpa Gupta, MD, FASCO avatar
⟳ Sia Daneshmand, M.D. retweeted
Shilpa Gupta, MD, FASCO@shilpaonc·Aug 30

Celebrating 20 yrs of @IBCG_BladderCA! Thanks @UroDocAsh for a memorable #IBCG26 and congratulations on IBCG’s tremendous growth & global impact. What makes this group special is our willingness to tackle difficult & controversial topics with openness, rigor and friendship to build consensuses that help guide the global bladder cancer community. Grateful for your leadership, mentorship, friendship and proud to serve on the Board. Here’s to the next 20! 🌎🎉

Post attachmentPost attachmentPost attachmentPost attachment
Sumanta K. Pal, MD, FASCO avatar
⟳ Sia Daneshmand, M.D. retweeted
Sumanta K. Pal, MD, FASCO@montypal·Aug 29

Kudos to Mamta Parikh, MD (@UCD_Cancer) & @ADESAIONCMD (@UCSFCancer), in association w @ANCO_News, for initiating the 1st #NorCal GU Research Forum. Modeled after the #SoCal meeting started by me & @siadaneshmand w @TDorffOnc, @AmarUKishan, @DrRanaMcKay & others ~5y ago now, this is going to be a phenomenal session in which the major centers across #NorCal convene to share insights on available regional #clinicaltrials. Great to see a tremendous list of GU experts on the agenda, incl (but not limited to!) @snseyedinMD, @mdallera, @johnleppert, @sandysrimd, @sumitshahMD, @SimaPorten, @koshkin85, @DrTFriedlander, @DivyaParikhMD & so many others! Join us on 9/19/26 at the @ClaremontHotel. More details here: anco.org/Genitourinary-Cance…

Post attachment
Shilpa Gupta, MD, FASCO avatar
⟳ Sia Daneshmand, M.D. retweeted
Shilpa Gupta, MD, FASCO@shilpaonc·Aug 28

Honored that our @IBCG_BladderCA consensus paper on "Optimal management of muscle-invasive bladder cancer" has received the @EUplatinum Impact Award as the most influential work in its June 2026 issue! Especially meaningful to see the 🌎 impact of this work, bringing together multidisciplinary expertise to help guide evidence-based care, treatment sequencing, and the next generation of clinical trials for patients with MIBC worldwide. Grateful to our co-authors, IBCG colleagues, and @UroDocAsh for his vision and commitment to improving bladder cancer outcomes. Thank you @Albert0Briganti for this amazing recognition! @CleClinicMD @CleClinicUro @caseccc @EurUrolOncol @Uroweb @WorldBladderCan @FaltasLab @Uromigos @OncoAlert @BladderCancerUS @SpiessPhilippe @GTumors Full paper here👇 doi.org/10.1016/j.eururo.202…

Post attachmentPost attachmentPost attachment